A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Latest Information Update: 12 May 2025
At a glance
Most Recent Events
- 06 May 2025 Planned End Date changed from 12 Jul 2025 to 18 Jul 2025.
- 16 Jul 2024 Planned End Date changed from 30 Jun 2025 to 12 Jul 2025.
- 15 Jul 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.